# A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours

> **NCT04414150** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Malignant Tumours

## Interventions

- **DRUG:** SHR-1802

## Key facts

- **NCT ID:** NCT04414150
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2022-01-13
- **Final completion:** 2022-03-15
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414150, "A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04414150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*